LAX.SH
NOVARTIS INDIA LIMITED·MISCELLANEOUS 56.63·Pharmaceuticals & Biotechnology Companies
Price
1,466.3
+0.95%52W Range
Market Cap
₹3,620.41 Cr
Traded: ₹6.62 Cr (0.18%) 0.0x
Free Float: ₹980.41 Cr (0.68% of FF traded)
Volume · 60D trend
44.71 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +8.0% | +11.0% | +12.0% | -- | -- | Accelerating |
| Return | +7.0% | +16.0% | +23.0% | +37.0% | -- | Accelerating |
| Profit | -7.0% | +35.0% | -3.0% | -- | -8.0% | Decelerating |
| Sales | -6.0% | -1.0% | -2.0% | -- | -1.0% | Stable |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 86 | 90 | 88 | 84 | 93 | 87 | 92 | 81 | 85 | 79 | 91 | 76 |
| Expenses | 70 | 64 | 66 | 60 | 60 | 67 | 69 | 68 | 70 | 65 | 62 | 73 | 67 |
| Operating Profit | 21 | 22 | 24 | 27 | 24 | 26 | 18 | 24 | 11 | 20 | 17 | 17 | 9 |
| OPM % | 23.0% | 26.0% | 26.0% | 31.0% | 29.0% | 28.0% | 21.0% | 26.0% | 14.0% | 23.0% | 21.0% | 19.0% | 12.0% |
| Other Income | 10 | 9 | 9 | 11 | 11 | 11 | 10 | 10 | 10 | 22 | 17 | 12 | 16 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 2 |
| Profit Before Tax | 30 | 30 | 33 | 37 | 34 | 35 | 28 | 34 | 21 | 41 | 32 | 28 | 23 |
| Tax % | 16.0% | 46.0% | 26.0% | 26.0% | 14.0% | 28.0% | 26.0% | 24.0% | 31.0% | 36.0% | 27.0% | 27.0% | -7.0% |
| Net Profit | 25 | 16 | 24 | 28 | 29 | 25 | 20 | 26 | 15 | 27 | 24 | 20 | 25 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 10.2 | 6.5 | 9.8 | 11.2 | 11.9 | 10.3 | 8.3 | 10.4 | 6.0 | 10.8 | 9.6 | 8.2 | 10.1 |
| Sales Growth (YoY) | 8.3% | -7.5% | 3.5% | -4.3% | 3.7% | 9.4% | 10.1% | 1.1% | 6.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 5.8% | -4.4% | 2.3% | 4.8% | -9.7% | 6.9% | -5.4% | 13.6% | -4.7% | 7.6% | -13.2% | 19.7% | -- |
| OP Growth (YoY) | -12.5% | -15.4% | 33.3% | 12.5% | 118.2% | 30.0% | 5.9% | 41.2% | 22.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | -4.5% | -8.3% | -11.1% | 12.5% | -7.7% | 44.4% | -25.0% | 118.2% | -45.0% | 17.6% | 0.0% | 88.9% | -- |
| Profit Growth (YoY) | -13.8% | -36.8% | 18.7% | 7.3% | 99.6% | -4.2% | -13.8% | 27.1% | -41.3% | 249.2% | 29.1% | -61.3% | 3.5% |
| EPS Growth (YoY) | -13.8% | -36.8% | 18.6% | 7.4% | 99.5% | -4.2% | -13.8% | 26.9% | -41.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 56.9% | -33.5% | -12.3% | -5.7% | 15.1% | 24.7% | -20.6% | 75.1% | -44.7% | 12.2% | 16.8% | -18.9% | -- |
| OP Margin | 23.1% | 25.6% | 26.7% | 30.7% | 28.6% | 28.0% | 20.7% | 26.1% | 13.6% | 23.5% | 21.5% | 18.7% | 11.8% |
| Net Margin | 27.5% | 18.6% | 26.7% | 31.8% | 34.5% | 26.9% | 23.0% | 28.3% | 18.5% | 31.8% | 30.4% | 22.0% | 32.9% |
| Material Cost % | 58.0% | 57.0% | 56.0% | 53.0% | 59.0% | 54.0% | 56.0% | 58.0% | 70.0% | 54.0% | 57.0% | 58.0% | 60.0% |
| Employee Cost % | 5.0% | 7.0% | 6.0% | 6.0% | 4.0% | 5.0% | 6.0% | 6.0% | 6.0% | 7.0% | 7.0% | 7.0% | 8.0% |
| P/S | 10.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 38.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation of the Closure of the Trading Window for Novartis India Limited ("the Company") for the quarter ended June 30, 2026.
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the captioned Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has informed BSE regarding Updates on Open offer for acquisition of up to 64,19,608 (sixty four lakhs nineteen thousand six hundred and eight) ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....
Axis Capital Ltd ("Manager to the Open Offer") has informed BSE regarding Open offer for acquisition of up to 64,19,608 (sixty four lakhs nineteen thousand six hundred and eight) fully ....
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of The Securities and Exchange Board of India (Substantial ....
Axis Capital Ltd ("Manager to the Open Offer") has informed BSE regarding the updates on Open offer for acquisition of up to 64,19,608 (sixty four lakhs nineteen thousand six hundred and ....
Intimation of Newspaper Advertisement of Novartis India Limited ("The Company/ The Target Company") regarding the reasoned recommendations of the Committee of Independent Directors ("IDC").
Intimation of sending Reminder to respective shareholders for transfer of Shares of Novartis India Limited ("The Company") to Investor Education & Protection Fund ("IEPF").
Annual Secretarial Compliance Report for the financial year ended March 31, 2026.
Declaration of Voting Results of the Postal Ballot of Novartis India Limited ("The Company") and Scrutinizer''s Report.
Declaration of Voting Results of the Postal ballot of Novartis India Limited ("The Company") and Scrutinizer''s report.
Newspaper publication of the corrigendum to the Notice of Postal Ballot for the appointment of Ms. Gowree Gokhale as an Independent Director dated April 16, 2026
Corrigendum to the Notice of Postal Ballot issued on April 16, 2026, for the appointment of Ms. Gowree Gokhale (DIN: 09351661) as an Independent Director.
Intimation of Newspaper advertisement by Novartis India Limited (''The Company'') regarding the publication of Audited Financial Results of the company for the quarter and financial year ....
Integrated Financial Results for the Quarter and Financial Year ended March 31, 2026.
Outcome of the Board Meeting held on Tuesday, May 12, 2026 to approve the Audited Financial Results for the Quarter and the Financial year ended March 31, 2026.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Intimation of Newspaper Advertisement by Novartis India Limited (''the Company'')- Completion of e-mailing of Notice of Postal Ballot to the Members of the Company.
Notice of Postal Ballot - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("Listing Regulations").
Certificate in terms of Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018 for the Quarter and Financial Year ended March 31, 2026, issued to Novartis India Limited ....
Intimation of Newspaper Advertisement by Novartis India Limited ("the Company")- Information regarding Postal Ballot/ E-Voting.
Disclosure under regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011).
Intimation of meeting of Board of Directors of Novartis India Limited("the Company") and Closure of Trading Window.
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve The Audited Financial Results ....
Intimation of the receipt of Delhi High Court Order admitting Company Petition in the matter of Novartis India Limited vs. Commissioner of Trade and Taxes (W.P.(C) 3892/2026)
Outcome of the meeting of Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 inter-alia to approve the appointment of Ms. Gowree Gokhale ....
Outcome of the meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 to inter-alia approve the appointment of Ms. Gowree Gokhale ....
Outcome of the meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 to inter-alia approve the completion of second tenure ....
This is to inform that Ms. Gowree Gokhale (DIN: 09351661) has been appointed as an Additional Director (designated as non-executive and Independent Director) w.e.f. April 01, 2026, for ....
Intimation is hereby given that an order for demand was received on March 27, 2026, under Section 156 of the Income Tax Act, 1961. Further, an Order in the same regard has been received ....
The Company would hereby like to intimate to the Stock Exchange that, the Company has received from manager to the open offer (Axis Capital Limited) the draft letter of offer dated March 05, 2026.
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer to the public shareholders of Novartis India Ltd ("Target Company").
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy Detailed Public Statement in terms of Regulation 3(1) and Regulation 4 read with Regulation 13(4), Regulation ....
The Detailed Public Statement ("DPS") in relation to the open offer received by Novartis India Limited ("the Company") dated Thursday, February 26, 2026.
Disclosure under Regulation 30 of SEBI LODR Regulations.
Axis Capital Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Novartis India Ltd under Regulation 3(1) ....
Receipt of Public Announcement in relation to open offer from Axis Capital Limited (Manager to the Open Offer).
This disclosure is filed pursuant to regulation 30 and 30A of SEBI LODR regulations read with clause 5A of Para A of Part A of Schedule III of the Listing Regulations.
Clarification regarding incorrect financial figures of Novartis India Limited for Q3 2025-26 reported in Free Press Journal article dated January 28, 2026. The article has now been taken down.
Intimation of newspaper advertisement by Novartis India Limited (''the Company'') regarding the publication of Unaudited Financial Results of the Company for the quarter ended December 31, 2025.
Integrated Filing (Financial) for the Quarter ended December 31, 2025.
Outcome of the Meeting of the Board of Directors of Novartis India Limited ("the Company") held on Wednesday, January 28, 2026.
Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations , 2018 for the quarter ended December 31, 2025, issued to Novartis India Limited ("The Company") ....
Held by ETFs
1 ETFs hold NOVARTIND · sorted by weight